nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Clonidine—SLC22A4—Crohn's disease	0.0555	0.571	CrCbGaD
Apraclonidine—Clonidine—SLC22A5—Crohn's disease	0.0417	0.429	CrCbGaD
Apraclonidine—Parosmia—Mesalazine—Crohn's disease	0.0237	0.0286	CcSEcCtD
Apraclonidine—Upset stomach—Mesalazine—Crohn's disease	0.0234	0.0283	CcSEcCtD
Apraclonidine—Rhinorrhoea—Mesalazine—Crohn's disease	0.019	0.0229	CcSEcCtD
Apraclonidine—Vasodilation—Mesalazine—Crohn's disease	0.0175	0.0211	CcSEcCtD
Apraclonidine—Vasodilation procedure—Mesalazine—Crohn's disease	0.0175	0.0211	CcSEcCtD
Apraclonidine—Endophthalmitis—Prednisone—Crohn's disease	0.0171	0.0206	CcSEcCtD
Apraclonidine—Dry eye—Mesalazine—Crohn's disease	0.0142	0.0171	CcSEcCtD
Apraclonidine—Eye pain—Mesalazine—Crohn's disease	0.0123	0.0149	CcSEcCtD
Apraclonidine—Libido decreased—Mesalazine—Crohn's disease	0.012	0.0145	CcSEcCtD
Apraclonidine—Disturbance in sexual arousal—Mesalazine—Crohn's disease	0.0111	0.0134	CcSEcCtD
Apraclonidine—Face oedema—Mesalazine—Crohn's disease	0.0108	0.013	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.0105	0.0126	CcSEcCtD
Apraclonidine—Abdominal discomfort—Azathioprine—Crohn's disease	0.0101	0.0123	CcSEcCtD
Apraclonidine—Oedema—Mercaptopurine—Crohn's disease	0.0101	0.0122	CcSEcCtD
Apraclonidine—Nasopharyngitis—Mesalazine—Crohn's disease	0.00997	0.012	CcSEcCtD
Apraclonidine—Skin disorder—Mercaptopurine—Crohn's disease	0.0098	0.0119	CcSEcCtD
Apraclonidine—Asthma—Mesalazine—Crohn's disease	0.00963	0.0116	CcSEcCtD
Apraclonidine—Infestation NOS—Azathioprine—Crohn's disease	0.00943	0.0114	CcSEcCtD
Apraclonidine—Infestation—Azathioprine—Crohn's disease	0.00943	0.0114	CcSEcCtD
Apraclonidine—Abdominal discomfort—Mesalazine—Crohn's disease	0.00924	0.0112	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.0092	0.0111	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00871	0.0105	CcSEcCtD
Apraclonidine—Infestation NOS—Mesalazine—Crohn's disease	0.00859	0.0104	CcSEcCtD
Apraclonidine—Infestation—Mesalazine—Crohn's disease	0.00859	0.0104	CcSEcCtD
Apraclonidine—Haemorrhage—Azathioprine—Crohn's disease	0.00847	0.0102	CcSEcCtD
Apraclonidine—Conjunctivitis—Mesalazine—Crohn's disease	0.00835	0.0101	CcSEcCtD
Apraclonidine—Rhinitis—Mesalazine—Crohn's disease	0.00773	0.00934	CcSEcCtD
Apraclonidine—Haemorrhage—Mesalazine—Crohn's disease	0.00771	0.00932	CcSEcCtD
Apraclonidine—Pharyngitis—Mesalazine—Crohn's disease	0.00765	0.00925	CcSEcCtD
Apraclonidine—Mediastinal disorder—Azathioprine—Crohn's disease	0.00763	0.00922	CcSEcCtD
Apraclonidine—Oedema peripheral—Mesalazine—Crohn's disease	0.0076	0.00918	CcSEcCtD
Apraclonidine—Arrhythmia—Azathioprine—Crohn's disease	0.00756	0.00914	CcSEcCtD
Apraclonidine—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00744	0.00899	CcSEcCtD
Apraclonidine—Eye disorder—Mesalazine—Crohn's disease	0.00721	0.00871	CcSEcCtD
Apraclonidine—Angiopathy—Mesalazine—Crohn's disease	0.007	0.00846	CcSEcCtD
Apraclonidine—Mediastinal disorder—Mesalazine—Crohn's disease	0.00695	0.0084	CcSEcCtD
Apraclonidine—Diarrhoea—Mercaptopurine—Crohn's disease	0.00691	0.00835	CcSEcCtD
Apraclonidine—Ill-defined disorder—Azathioprine—Crohn's disease	0.00684	0.00827	CcSEcCtD
Apraclonidine—Mental disorder—Mesalazine—Crohn's disease	0.00676	0.00817	CcSEcCtD
Apraclonidine—Erythema—Mesalazine—Crohn's disease	0.00671	0.00811	CcSEcCtD
Apraclonidine—Malaise—Azathioprine—Crohn's disease	0.00665	0.00803	CcSEcCtD
Apraclonidine—Tension—Mesalazine—Crohn's disease	0.00659	0.00796	CcSEcCtD
Apraclonidine—Dysgeusia—Mesalazine—Crohn's disease	0.00657	0.00795	CcSEcCtD
Apraclonidine—Nervousness—Mesalazine—Crohn's disease	0.00652	0.00788	CcSEcCtD
Apraclonidine—Vomiting—Mercaptopurine—Crohn's disease	0.00642	0.00776	CcSEcCtD
Apraclonidine—Dermatitis—Mercaptopurine—Crohn's disease	0.00636	0.00769	CcSEcCtD
Apraclonidine—Vision blurred—Mesalazine—Crohn's disease	0.00633	0.00765	CcSEcCtD
Apraclonidine—Myalgia—Azathioprine—Crohn's disease	0.00627	0.00758	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.00623	0.00753	CcSEcCtD
Apraclonidine—Ill-defined disorder—Mesalazine—Crohn's disease	0.00623	0.00753	CcSEcCtD
Apraclonidine—Discomfort—Azathioprine—Crohn's disease	0.0062	0.00749	CcSEcCtD
Apraclonidine—Malaise—Mesalazine—Crohn's disease	0.00605	0.00732	CcSEcCtD
Apraclonidine—Syncope—Mesalazine—Crohn's disease	0.00602	0.00728	CcSEcCtD
Apraclonidine—Nausea—Mercaptopurine—Crohn's disease	0.006	0.00725	CcSEcCtD
Apraclonidine—Infection—Azathioprine—Crohn's disease	0.00598	0.00722	CcSEcCtD
Apraclonidine—Palpitations—Mesalazine—Crohn's disease	0.00593	0.00717	CcSEcCtD
Apraclonidine—Skin disorder—Azathioprine—Crohn's disease	0.00584	0.00706	CcSEcCtD
Apraclonidine—Chest pain—Mesalazine—Crohn's disease	0.00571	0.00691	CcSEcCtD
Apraclonidine—Myalgia—Mesalazine—Crohn's disease	0.00571	0.00691	CcSEcCtD
Apraclonidine—Face oedema—Prednisone—Crohn's disease	0.00569	0.00688	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.00568	0.00686	CcSEcCtD
Apraclonidine—Discomfort—Mesalazine—Crohn's disease	0.00565	0.00683	CcSEcCtD
Apraclonidine—Irritability—Prednisone—Crohn's disease	0.00563	0.0068	CcSEcCtD
Apraclonidine—Dry mouth—Mesalazine—Crohn's disease	0.00559	0.00676	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.00548	0.00662	CcSEcCtD
Apraclonidine—Oedema—Mesalazine—Crohn's disease	0.00548	0.00662	CcSEcCtD
Apraclonidine—Infection—Mesalazine—Crohn's disease	0.00544	0.00658	CcSEcCtD
Apraclonidine—Nervous system disorder—Mesalazine—Crohn's disease	0.00537	0.00649	CcSEcCtD
Apraclonidine—Skin disorder—Mesalazine—Crohn's disease	0.00532	0.00643	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.00519	0.00628	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.00499	0.00603	CcSEcCtD
Apraclonidine—Feeling abnormal—Azathioprine—Crohn's disease	0.00496	0.00599	CcSEcCtD
Apraclonidine—Insomnia—Mesalazine—Crohn's disease	0.00495	0.00599	CcSEcCtD
Apraclonidine—Paraesthesia—Mesalazine—Crohn's disease	0.00492	0.00595	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Azathioprine—Crohn's disease	0.00492	0.00594	CcSEcCtD
Apraclonidine—Dyspnoea—Mesalazine—Crohn's disease	0.00488	0.0059	CcSEcCtD
Apraclonidine—Somnolence—Mesalazine—Crohn's disease	0.00487	0.00589	CcSEcCtD
Apraclonidine—Abdominal pain—Azathioprine—Crohn's disease	0.00475	0.00575	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.00473	0.00572	CcSEcCtD
Apraclonidine—Fatigue—Mesalazine—Crohn's disease	0.00472	0.00571	CcSEcCtD
Apraclonidine—Pain—Mesalazine—Crohn's disease	0.00468	0.00566	CcSEcCtD
Apraclonidine—Constipation—Mesalazine—Crohn's disease	0.00468	0.00566	CcSEcCtD
Apraclonidine—Feeling abnormal—Mesalazine—Crohn's disease	0.00451	0.00546	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Mesalazine—Crohn's disease	0.00448	0.00542	CcSEcCtD
Apraclonidine—Hypersensitivity—Azathioprine—Crohn's disease	0.00443	0.00536	CcSEcCtD
Apraclonidine—Abdominal pain—Mesalazine—Crohn's disease	0.00433	0.00524	CcSEcCtD
Apraclonidine—Bradycardia—Prednisone—Crohn's disease	0.00415	0.00502	CcSEcCtD
Apraclonidine—Diarrhoea—Azathioprine—Crohn's disease	0.00412	0.00497	CcSEcCtD
Apraclonidine—Haemorrhage—Prednisone—Crohn's disease	0.00408	0.00493	CcSEcCtD
Apraclonidine—Hypersensitivity—Mesalazine—Crohn's disease	0.00404	0.00488	CcSEcCtD
Apraclonidine—Dizziness—Azathioprine—Crohn's disease	0.00398	0.00481	CcSEcCtD
Apraclonidine—Asthenia—Mesalazine—Crohn's disease	0.00393	0.00475	CcSEcCtD
Apraclonidine—Pruritus—Mesalazine—Crohn's disease	0.00388	0.00469	CcSEcCtD
Apraclonidine—Vomiting—Azathioprine—Crohn's disease	0.00382	0.00462	CcSEcCtD
Apraclonidine—Eye disorder—Prednisone—Crohn's disease	0.00381	0.00461	CcSEcCtD
Apraclonidine—Dermatitis—Azathioprine—Crohn's disease	0.00379	0.00458	CcSEcCtD
Apraclonidine—Headache—Azathioprine—Crohn's disease	0.00377	0.00455	CcSEcCtD
Apraclonidine—Diarrhoea—Mesalazine—Crohn's disease	0.00375	0.00453	CcSEcCtD
Apraclonidine—Angiopathy—Prednisone—Crohn's disease	0.0037	0.00447	CcSEcCtD
Apraclonidine—Arrhythmia—Prednisone—Crohn's disease	0.00364	0.00441	CcSEcCtD
Apraclonidine—Dizziness—Mesalazine—Crohn's disease	0.00362	0.00438	CcSEcCtD
Apraclonidine—Mental disorder—Prednisone—Crohn's disease	0.00357	0.00432	CcSEcCtD
Apraclonidine—Nausea—Azathioprine—Crohn's disease	0.00357	0.00432	CcSEcCtD
Apraclonidine—Erythema—Prednisone—Crohn's disease	0.00355	0.00429	CcSEcCtD
Apraclonidine—Vomiting—Mesalazine—Crohn's disease	0.00348	0.00421	CcSEcCtD
Apraclonidine—Dermatitis—Mesalazine—Crohn's disease	0.00345	0.00417	CcSEcCtD
Apraclonidine—Headache—Mesalazine—Crohn's disease	0.00343	0.00415	CcSEcCtD
Apraclonidine—Vision blurred—Prednisone—Crohn's disease	0.00335	0.00405	CcSEcCtD
Apraclonidine—Ill-defined disorder—Prednisone—Crohn's disease	0.0033	0.00398	CcSEcCtD
Apraclonidine—Nausea—Mesalazine—Crohn's disease	0.00325	0.00393	CcSEcCtD
Apraclonidine—Malaise—Prednisone—Crohn's disease	0.0032	0.00387	CcSEcCtD
Apraclonidine—Syncope—Prednisone—Crohn's disease	0.00318	0.00385	CcSEcCtD
Apraclonidine—Myalgia—Prednisone—Crohn's disease	0.00302	0.00365	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.003	0.00363	CcSEcCtD
Apraclonidine—Discomfort—Prednisone—Crohn's disease	0.00299	0.00361	CcSEcCtD
Apraclonidine—Oedema—Prednisone—Crohn's disease	0.0029	0.0035	CcSEcCtD
Apraclonidine—Infection—Prednisone—Crohn's disease	0.00288	0.00348	CcSEcCtD
Apraclonidine—Nervous system disorder—Prednisone—Crohn's disease	0.00284	0.00344	CcSEcCtD
Apraclonidine—Skin disorder—Prednisone—Crohn's disease	0.00282	0.0034	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.00264	0.00319	CcSEcCtD
Apraclonidine—Insomnia—Prednisone—Crohn's disease	0.00262	0.00317	CcSEcCtD
Apraclonidine—Paraesthesia—Prednisone—Crohn's disease	0.0026	0.00315	CcSEcCtD
Apraclonidine—Fatigue—Prednisone—Crohn's disease	0.0025	0.00302	CcSEcCtD
Apraclonidine—Constipation—Prednisone—Crohn's disease	0.00248	0.003	CcSEcCtD
Apraclonidine—Feeling abnormal—Prednisone—Crohn's disease	0.00239	0.00289	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Prednisone—Crohn's disease	0.00237	0.00287	CcSEcCtD
Apraclonidine—Abdominal pain—Prednisone—Crohn's disease	0.00229	0.00277	CcSEcCtD
Apraclonidine—Hypersensitivity—Prednisone—Crohn's disease	0.00214	0.00258	CcSEcCtD
Apraclonidine—Asthenia—Prednisone—Crohn's disease	0.00208	0.00251	CcSEcCtD
Apraclonidine—Pruritus—Prednisone—Crohn's disease	0.00205	0.00248	CcSEcCtD
Apraclonidine—Diarrhoea—Prednisone—Crohn's disease	0.00198	0.0024	CcSEcCtD
Apraclonidine—Dizziness—Prednisone—Crohn's disease	0.00192	0.00232	CcSEcCtD
Apraclonidine—Vomiting—Prednisone—Crohn's disease	0.00184	0.00223	CcSEcCtD
Apraclonidine—Dermatitis—Prednisone—Crohn's disease	0.00183	0.00221	CcSEcCtD
Apraclonidine—Headache—Prednisone—Crohn's disease	0.00182	0.00219	CcSEcCtD
Apraclonidine—Nausea—Prednisone—Crohn's disease	0.00172	0.00208	CcSEcCtD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000317	0.0042	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.000315	0.00417	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—GPR65—Crohn's disease	0.000313	0.00414	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—Crohn's disease	0.000308	0.00408	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—F5—Crohn's disease	0.000307	0.00406	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—MLN—Crohn's disease	0.000307	0.00406	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.000301	0.00398	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—MLN—Crohn's disease	0.000295	0.00391	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—CCR6—Crohn's disease	0.000294	0.00389	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.000293	0.00387	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—IL3—Crohn's disease	0.00029	0.00384	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—ACKR2—Crohn's disease	0.000283	0.00374	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—RASGRP1—Crohn's disease	0.00028	0.00371	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000277	0.00367	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—CCR6—Crohn's disease	0.000274	0.00363	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—MLN—Crohn's disease	0.000274	0.00363	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—MLN—Crohn's disease	0.000268	0.00355	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—IL2RA—Crohn's disease	0.000268	0.00354	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—ACKR2—Crohn's disease	0.000263	0.00348	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—PTGER4—Crohn's disease	0.000259	0.00342	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000258	0.00341	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CCR9—Crohn's disease	0.000251	0.00332	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—IL2RA—Crohn's disease	0.00025	0.00331	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—F5—Crohn's disease	0.000249	0.0033	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—MLN—Crohn's disease	0.000249	0.0033	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—PTGER4—Crohn's disease	0.000242	0.0032	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—CCR6—Crohn's disease	0.00024	0.00318	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CCR9—Crohn's disease	0.000234	0.0031	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—GPR65—Crohn's disease	0.000233	0.00308	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CCR9—Crohn's disease	0.000228	0.00301	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—CCR6—Crohn's disease	0.000223	0.00295	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—GPR65—Crohn's disease	0.000218	0.00288	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CCR9—Crohn's disease	0.000213	0.00281	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—GPR65—Crohn's disease	0.000212	0.0028	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—PTGER4—Crohn's disease	0.000211	0.0028	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CCR9—Crohn's disease	0.000205	0.00271	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ACKR2—Crohn's disease	0.000205	0.00271	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—IL2RA—Crohn's disease	0.000203	0.00269	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—ITGA4—Crohn's disease	0.000202	0.00267	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PLA2G4F—Crohn's disease	0.000198	0.00262	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—GPR65—Crohn's disease	0.000198	0.00262	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—IL3—Crohn's disease	0.000197	0.00261	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—PTGER4—Crohn's disease	0.000196	0.0026	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MLN—Crohn's disease	0.000194	0.00257	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—ALB—Crohn's disease	0.000194	0.00256	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ACKR2—Crohn's disease	0.000191	0.00253	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—RASGRP1—Crohn's disease	0.00019	0.00252	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—GPR65—Crohn's disease	0.00019	0.00252	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CCR9—Crohn's disease	0.00019	0.00252	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—ITGA4—Crohn's disease	0.000189	0.0025	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCR9—Crohn's disease	0.000186	0.00246	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—IL3—Crohn's disease	0.000184	0.00244	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MLN—Crohn's disease	0.000181	0.0024	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—ALB—Crohn's disease	0.000181	0.00239	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	0.00018	0.00238	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—RASGRP1—Crohn's disease	0.000178	0.00236	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TAGAP—Crohn's disease	0.000177	0.00235	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—GPR65—Crohn's disease	0.000177	0.00234	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—GPR65—Crohn's disease	0.000173	0.00229	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCR9—Crohn's disease	0.000173	0.00229	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—MTMR3—Crohn's disease	0.000168	0.00223	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	0.000168	0.00223	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ACKR2—Crohn's disease	0.000167	0.00221	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CCR6—Crohn's disease	0.000166	0.0022	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TAGAP—Crohn's disease	0.000166	0.00219	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PLA2G4F—Crohn's disease	0.000161	0.00213	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—GPR65—Crohn's disease	0.00016	0.00213	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MLN—Crohn's disease	0.000158	0.0021	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—Crohn's disease	0.000157	0.00208	CbGpPWpGaD
Apraclonidine—ADRA2B—G alpha (i) signalling events—CXCL8—Crohn's disease	0.000156	0.00207	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ACKR2—Crohn's disease	0.000155	0.00206	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CCR6—Crohn's disease	0.000155	0.00205	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RSPO3—Crohn's disease	0.000155	0.00205	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—ITGA4—Crohn's disease	0.000153	0.00203	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CCR6—Crohn's disease	0.000151	0.002	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	0.00015	0.00199	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—IL3—Crohn's disease	0.000149	0.00198	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MLN—Crohn's disease	0.000147	0.00195	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SEL1L—Crohn's disease	0.000147	0.00195	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—ALB—Crohn's disease	0.000147	0.00194	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—PTGER4—Crohn's disease	0.000146	0.00193	CbGpPWpGaD
Apraclonidine—ADRA2C—G alpha (i) signalling events—CXCL8—Crohn's disease	0.000146	0.00193	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TAGAP—Crohn's disease	0.000145	0.00192	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RSPO3—Crohn's disease	0.000145	0.00192	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—RASGRP1—Crohn's disease	0.000145	0.00191	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CCR6—Crohn's disease	0.000141	0.00186	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—IL2RA—Crohn's disease	0.000138	0.00183	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SEL1L—Crohn's disease	0.000137	0.00182	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—MTMR3—Crohn's disease	0.000137	0.00181	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—PTGER4—Crohn's disease	0.000136	0.00181	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	0.000136	0.00181	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CCR6—Crohn's disease	0.000136	0.00179	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TAGAP—Crohn's disease	0.000135	0.00178	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCR9—Crohn's disease	0.000134	0.00178	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PTGER4—Crohn's disease	0.000133	0.00176	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—FADS1—Crohn's disease	0.000131	0.00174	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—IL2RA—Crohn's disease	0.000129	0.00171	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RSPO3—Crohn's disease	0.000127	0.00168	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CCR6—Crohn's disease	0.000126	0.00167	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCR9—Crohn's disease	0.000126	0.00166	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—GPR65—Crohn's disease	0.000125	0.00165	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—IL3—Crohn's disease	0.000124	0.00165	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000124	0.00165	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PTGER4—Crohn's disease	0.000124	0.00164	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCR6—Crohn's disease	0.000123	0.00163	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GPX4—Crohn's disease	0.000123	0.00163	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—RASGRP1—Crohn's disease	0.00012	0.00159	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SEL1L—Crohn's disease	0.00012	0.00159	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PTGER4—Crohn's disease	0.000119	0.00158	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GCKR—Crohn's disease	0.000119	0.00157	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—CXCL8—Crohn's disease	0.000119	0.00157	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RSPO3—Crohn's disease	0.000118	0.00156	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GPR65—Crohn's disease	0.000117	0.00155	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—IL3—Crohn's disease	0.000116	0.00154	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000116	0.00154	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCR6—Crohn's disease	0.000114	0.00151	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL3—Crohn's disease	0.000113	0.0015	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000112	0.00149	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SEL1L—Crohn's disease	0.000112	0.00148	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PTGER4—Crohn's disease	0.000111	0.00147	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCR9—Crohn's disease	0.00011	0.00145	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—RASGRP1—Crohn's disease	0.000109	0.00145	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PTGER4—Crohn's disease	0.000108	0.00143	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—FADS1—Crohn's disease	0.000107	0.00141	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL3—Crohn's disease	0.000106	0.0014	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—IL2RA—Crohn's disease	0.000105	0.00139	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—RASGRP1—Crohn's disease	0.000102	0.00135	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GPR65—Crohn's disease	0.000102	0.00135	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCR9—Crohn's disease	0.000102	0.00135	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—IL3—Crohn's disease	0.000102	0.00135	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000101	0.00134	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PTGER4—Crohn's disease	0.000101	0.00133	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GPX4—Crohn's disease	9.98e-05	0.00132	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—ALB—Crohn's disease	9.97e-05	0.00132	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—RASGRP1—Crohn's disease	9.83e-05	0.0013	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GCKR—Crohn's disease	9.64e-05	0.00128	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GPR65—Crohn's disease	9.48e-05	0.00126	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—CXCL8—Crohn's disease	9.46e-05	0.00125	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—IL3—Crohn's disease	9.44e-05	0.00125	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	9.43e-05	0.00125	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—ALB—Crohn's disease	9.32e-05	0.00123	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—JAK2—Crohn's disease	9.27e-05	0.00123	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL3—Crohn's disease	9.23e-05	0.00122	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—RASGRP1—Crohn's disease	9.13e-05	0.00121	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—RASGRP1—Crohn's disease	8.93e-05	0.00118	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCR6—Crohn's disease	8.9e-05	0.00118	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—CXCL8—Crohn's disease	8.84e-05	0.00117	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—IL2RA—Crohn's disease	8.72e-05	0.00115	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—JAK2—Crohn's disease	8.66e-05	0.00115	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL3—Crohn's disease	8.58e-05	0.00114	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCR6—Crohn's disease	8.32e-05	0.0011	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—RASGRP1—Crohn's disease	8.29e-05	0.0011	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—IL2RA—Crohn's disease	8.14e-05	0.00108	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RBX1—Crohn's disease	8.05e-05	0.00107	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL2RA—Crohn's disease	7.92e-05	0.00105	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PTGER4—Crohn's disease	7.84e-05	0.00104	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—CXCL8—Crohn's disease	7.73e-05	0.00102	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	7.7e-05	0.00102	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—ALB—Crohn's disease	7.57e-05	0.001	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RBX1—Crohn's disease	7.52e-05	0.000996	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL2RA—Crohn's disease	7.4e-05	0.000979	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PTGER4—Crohn's disease	7.32e-05	0.00097	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCR6—Crohn's disease	7.27e-05	0.000963	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—CXCL8—Crohn's disease	7.18e-05	0.000951	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—IL2RA—Crohn's disease	7.12e-05	0.000943	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—UBE2D1—Crohn's disease	7.06e-05	0.000935	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—JAK2—Crohn's disease	7.04e-05	0.000932	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RIPK2—Crohn's disease	6.85e-05	0.000907	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCR6—Crohn's disease	6.76e-05	0.000895	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL3—Crohn's disease	6.68e-05	0.000884	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—IL2RA—Crohn's disease	6.62e-05	0.000876	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—UBE2D1—Crohn's disease	6.6e-05	0.000873	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RBX1—Crohn's disease	6.58e-05	0.000871	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL2RA—Crohn's disease	6.47e-05	0.000856	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RASGRP1—Crohn's disease	6.46e-05	0.000855	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PTGER4—Crohn's disease	6.4e-05	0.000848	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RIPK2—Crohn's disease	6.4e-05	0.000847	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL3—Crohn's disease	6.24e-05	0.000826	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RBX1—Crohn's disease	6.11e-05	0.000809	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RASGRP1—Crohn's disease	6.03e-05	0.000799	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL2RA—Crohn's disease	6.01e-05	0.000795	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTGER4—Crohn's disease	5.95e-05	0.000788	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—JAK2—Crohn's disease	5.86e-05	0.000776	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SOCS1—Crohn's disease	5.85e-05	0.000775	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—UBE2D1—Crohn's disease	5.77e-05	0.000763	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RIPK2—Crohn's disease	5.59e-05	0.00074	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—TYK2—Crohn's disease	5.58e-05	0.000739	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—JAK2—Crohn's disease	5.47e-05	0.000725	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SOCS1—Crohn's disease	5.47e-05	0.000724	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL3—Crohn's disease	5.45e-05	0.000722	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—UBE2D1—Crohn's disease	5.36e-05	0.000709	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CXCL8—Crohn's disease	5.35e-05	0.000708	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—JAK2—Crohn's disease	5.32e-05	0.000705	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RASGRP1—Crohn's disease	5.27e-05	0.000698	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—TYK2—Crohn's disease	5.21e-05	0.00069	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RIPK2—Crohn's disease	5.19e-05	0.000688	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL3—Crohn's disease	5.07e-05	0.000671	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SMAD3—Crohn's disease	5.05e-05	0.000669	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CXCL8—Crohn's disease	5e-05	0.000662	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—JAK2—Crohn's disease	4.97e-05	0.000658	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RASGRP1—Crohn's disease	4.9e-05	0.000649	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CXCL8—Crohn's disease	4.86e-05	0.000643	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—JAK2—Crohn's disease	4.79e-05	0.000634	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SOCS1—Crohn's disease	4.78e-05	0.000633	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SMAD3—Crohn's disease	4.72e-05	0.000625	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL2RA—Crohn's disease	4.68e-05	0.000619	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—TYK2—Crohn's disease	4.56e-05	0.000603	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CXCL8—Crohn's disease	4.54e-05	0.000601	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—JAK2—Crohn's disease	4.45e-05	0.000589	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SOCS1—Crohn's disease	4.44e-05	0.000588	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL2RA—Crohn's disease	4.37e-05	0.000579	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CXCL8—Crohn's disease	4.37e-05	0.000578	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—JAK2—Crohn's disease	4.35e-05	0.000575	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—TYK2—Crohn's disease	4.23e-05	0.00056	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SMAD3—Crohn's disease	4.12e-05	0.000546	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCL8—Crohn's disease	4.06e-05	0.000537	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—JAK2—Crohn's disease	4.04e-05	0.000535	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCL8—Crohn's disease	3.97e-05	0.000525	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SMAD3—Crohn's disease	3.83e-05	0.000507	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL2RA—Crohn's disease	3.82e-05	0.000506	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALB—Crohn's disease	3.78e-05	0.0005	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCL8—Crohn's disease	3.69e-05	0.000488	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL2RA—Crohn's disease	3.55e-05	0.00047	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTGS2—Crohn's disease	3.3e-05	0.000438	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TYK2—Crohn's disease	3.3e-05	0.000436	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—JAK2—Crohn's disease	3.14e-05	0.000416	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TYK2—Crohn's disease	3.08e-05	0.000408	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALB—Crohn's disease	3.07e-05	0.000406	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—JAK2—Crohn's disease	2.94e-05	0.000389	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCL8—Crohn's disease	2.87e-05	0.00038	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—Crohn's disease	2.73e-05	0.000361	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TYK2—Crohn's disease	2.69e-05	0.000356	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS2—Crohn's disease	2.68e-05	0.000355	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCL8—Crohn's disease	2.68e-05	0.000355	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—JAK2—Crohn's disease	2.57e-05	0.00034	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—Crohn's disease	2.55e-05	0.000337	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TYK2—Crohn's disease	2.5e-05	0.000331	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—JAK2—Crohn's disease	2.39e-05	0.000316	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL8—Crohn's disease	2.34e-05	0.00031	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—STAT3—Crohn's disease	2.31e-05	0.000306	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—Crohn's disease	2.23e-05	0.000295	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL8—Crohn's disease	2.18e-05	0.000288	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—STAT3—Crohn's disease	2.16e-05	0.000285	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—Crohn's disease	2.07e-05	0.000274	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—STAT3—Crohn's disease	1.88e-05	0.000249	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—STAT3—Crohn's disease	1.75e-05	0.000232	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—Crohn's disease	1.61e-05	0.000213	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—Crohn's disease	1.51e-05	0.000199	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—Crohn's disease	1.32e-05	0.000174	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—Crohn's disease	1.22e-05	0.000162	CbGpPWpGaD
